Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Found 181 studies with search of: | "Epirubicin" |
Rank | Status | Study | ||||
---|---|---|---|---|---|---|
1 | Terminated |
Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer
|
||||
2 | Recruiting |
Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients
|
||||
3 | Active, not recruiting |
Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer
|
||||
4 | Recruiting |
Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer
|
||||
5 | Recruiting |
Epirubicin or Not in Patients With TOP2A (Topoisomerase (DNA) II Alpha (170kD)) Normal Early Breast Cancer
|
||||
6 | Recruiting |
A Phase I, Open-Label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors.
|
||||
7 | Recruiting |
Neoadjuvant Endostatin and Chemotherapy for Breast Cancer
|
||||
8 | Completed |
Study of Docetaxel in Breast Cancer Patients
|
||||
9 | Recruiting |
Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer Patients
|
||||
10 | Recruiting |
Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast Cancer
|
||||
11 | Recruiting |
Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates
|
||||
12 | Completed |
Randomized Phase III Trial With Docetaxel Plus Epirubicine Versus Docetaxel Plus Capecitabine for Metastatic Breast Cancer
|
||||
13 | Active, not recruiting |
Adjuvant Treatment of Breast Cancer With 1-3 Aflicted Lymph Nodes
|
||||
14 | Recruiting |
Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer
|
||||
15 | Active, not recruiting |
Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility
|
||||
16 | Recruiting |
REAL 3 Version 1.3: Trial of the Efficacy of Epirubicin, Oxaliplatin and Capecitabine (EOX) With or Without Panitumumab in Previously Untreated Advanced Oesophago-Gastric Cancer
|
||||
17 | Recruiting |
A Phase III Trials Program Exploring the Integration of Bevacizumab, Everolimus (RAD001), and Lapatinib Into Current Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer
|
||||
18 | Completed |
EC (Epirubicin, Cyclophosphamide) Followed by T (Docetaxel) Versus ET (Epirubicin, Docetaxel) Followed by X (Capecitabine) as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer Patients
|
||||
19 | Active, not recruiting |
Epirubicin and Cyclophosphamide Compared With Epirubicin and Paclitaxel in Treating Women With Metastatic Breast Cancer
|
||||
20 | Completed |
Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies
|
Previous Page | Studies Shown (1-20) | Next Page (21-40) |